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Abstract
Significant progresses have been made in the inorganic and organic chemistry up to the 
present concerning the synthesis, characterization, and application of the metal com-
plexes of pharmaceutical substances. From the wide range of fields in which these coordi-
nation compounds find their application, many efforts were focused on the study of their 
importance in the biological processes. The coordination complexes of many pharmaceu-
tical substances having different pharmacological effects e.g., pyrazinamide (PZA), nico-
tinamide (NAM), nicotinic acid (NIC), theophylline (TEO), captopril (CPL), tolbutamide 
(TBA), clonidine (CLN), guanfacine (GUAF), etc. with transition metals were synthesized 
and used in order to improve their pharmacological and pharmacotechnical properties 
and also for the drug analysis and control. Several techniques such as Fourier transform 
infrared spectroscopy (FTIR), Raman spectroscopy, surface-enhanced Raman spectros-
copy (SERS), X-ray spectroscopy, mass spectrometry, ultraviolet-visible (UV-Vis) spec-
trophotometry, electron paramagnetic resonance (EPR) spectroscopy, X-ray diffraction, 
elemental analysis, electrochemical methods, thermal methods, and scanning electron 
microscopy were used for the physicochemical characterization of the complex com-
position. A significant interest in the development of metal complex-based drugs with 
unique research and therapeutic and diagnostic opportunities is currently observed in 
the medicinal inorganic chemistry area.
Keywords: coordination complexes, transition metals, pharmaceutical substances, 
characterization methods, medicinal chemistry
1. Introduction
The coordination complexes have been studied since 1798 starting with the Tassaert stud-
ies, and till nowadays significant progresses have been made in the inorganic and organic 
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 chemistry concerning the synthesis, characterization, and application of this large group of 
metal complexes. Concerning their structure, complexes were considered those compounds 
which do not fit within the classical theory of valence, meaning that the combination ratio of 
the elements exceeded their valences. This coordination theory elaborated by Alfred Werner 
indicated that the secondary valences of the elements are involved in the formation of the 
second-order combinations leading to the actual representation of the complexes formed by 
the first coordination sphere marked between brackets [central atom (ligand)] and the second 
coordination sphere (ionization sphere) coming outside of the brackets. The central atom can 
be any chemical element; meanwhile, the ligands can be ions, atoms, or neutral molecules, 
which can act as donors [1]. Neutral molecules or mono-/polyatomic anions which have one or 
more unshared electron pairs can act as mono-/polydentate ligands, the latter ones form com-
plexes with cyclic structure known as chelates. A large number of pharmaceutical substances 
behave in vivo or in vitro conditions as ligands and chelating agents [2].
The number and the large structural variety of these complexes could not allow a rigorous 
systematization, even though some attempts by using certain classification criteria have been 
made such as the number of the central atoms, the charge of the complex ion, the type of 
ligands, and the coordination number. The coordination compounds were classified into 
Werner complexes, complexes with metal-metal bonds, metal carbonyls, clusters, complexes 
with macrocyclic ligands, molecular complexes (adducts, clathrates), chelates, and metal-
organic complexes [1].
Natural metal complexes consisting of a central metal atom or ion (especially of the 3D transi-
tion metals) are involved in a plenty of biological mechanisms among which photosynthesis, 
transport of oxygen in blood, coordination of some metabolic processes, pathological states, 
enzymatic reactions, etc., even though the metallic ions represent only 3% of the body com-
position. Many biomolecules (amino acids, peptides, carboxylic acids, etc.) can form metal 
complexes with different stabilities having biomedical importance. Some drugs have a certain 
therapeutic effect (e.g., antimicrobial, diuretic, antidepressant) due to the complexation of 
the metallic ion (Cu2+, Zn2+, Fe2+, Mg2+, etc.) essential for a certain biochemical process. Metal 
complexes and products containing oligoelements are widely used in therapy due to their 
pharmacodynamic properties, bioavailability enhancement, and toxicity decrease of some 
metal ions [1].
The main aspects concerning the formation of complexes between pharmaceutical substances 
and various ligands are supported by several observations. According to the biological, physi-
ological, and pathophysiological role of metal ions and ligands with pharmacological effect, 
metal ions present a great importance in carrying out the vital functions of living organ-
isms acting as complexes or chelates and also in the analysis and control methods of drug 
substances by forming complexes that can be detected by spectral techniques. The use of 
ligands, chelating agents, or complexes in medicine and biology concerns several purposes 
such as antidotes in poisoning with metal ions or hydrocyanic acid or cyanides; introduction 
in the living organisms of some essential metal ions found to be deficient; depriving bacteria, 
viruses, or microbial enzyme systems of micronutrients essential for their work; or providing 
toxic metals for the pathogenic agents [2].
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Many coordination complexes have been used in medicine containing metals such as plati-
num (cisplatin as anticancer chemotherapy drug), gold (as auranofin used for rheumatoid 
arthritis), technetium and rhenium (as radiopharmaceuticals used in imaging and radiother-
apy), ruthenium (as anticancer drug), gadolinium, cobalt, lithium, bismuth, iron, calcium, 
lanthanum, gallium, tin, arsenic, rhodium, copper, zinc, aluminum, lutetium, vanadium, 
manganese, etc. [3, 4]. Only a reduced number of Co(III) complexes can be mentioned as 
having biochemical properties: vitamin B12, a natural organometallic complex of Co(III) with glyoxime. Other important examples are the series of Co(III) complexes containing N- and 
O-donor ligands based on a chelating Schiff base (imidazole, methylimidazole) with effi-
ciency in the treatment of epithelial herpetic keratitis (the molecular target is supposed to be a 
virus protease containing histidine), adenovirus keratoconjunctivitis, and human immunode-
ficiency virus type 1. [Co(NH3)6]Cl3 presents potent antiviral activity (against Sindbis virus). Some studies reported also the antibacterial activity of Co(II) and Co(III) complexes against 
Bacillus subtilis, Enterobacter aeruginosa, Escherichia coli, Staphylococcus aureus, etc. [3].
It was demonstrated that the antibacterial activity was increased upon chelation making the 
ligand a more powerful agent [5, 6]. The complexation of derivatives of sterically hindered 
o-diphenols and o-aminophenols with Cu(II), Co(II), Ni(II), and Zn(II) ions exhibited anti-
oxidant, antiviral, and antimicrobial activity with low toxicity. Their synthesis, their sepa-
ration as crystalline powders, the composition, and physicochemical characteristics of the 
complexes were also studied in Ref. [7].
Metal complexes have become an emerging tool in drug discovery being widely used as thera-
peutic compounds to treat several human diseases such as carcinomas, lymphomas, infection con-
trol, diabetes, anti-inflammatory, and neurological disorders [8, 9]. Due to various implications 
and applications of complexes (especially the chelates) in the biomedical field, many aspects are 
required to be studied such as their nature, their stability, the factors determining their formation 
and stability, and possibilities for preventing some reactions and for releasing a metal ion from a 
complex; all these are necessary in order to understand how they act in biological processes [2].
2. Physicochemical characterization of metal complexes of some 
pharmaceuticals
The coordination complexes of a wide range of pharmaceutical substances [pyrazinamide 
(PZA), nicotinamide (NAM), nicotinic acid (NIC), tolbutamide (TBA), theophylline (TEO), cap-
topril (CFL), clonidine (CLN), and guanfacine (GUAF)] with transition metals [Cu(II), Cd(II), 
Ni(II), Mn(II), Zn(II), and Co(II)] were synthesized and then characterized by using various tech-
niques such as elemental analysis, spectral, electrochemical, thermal, and microscopic methods.
2.1. Metal complexes of pyrazinamide
Pyrazinamide (PZA) (pyrazine carboxamide) is a nicotinamide analogue used as a first-line drug 
to treat tuberculosis. The complexes of PZA with Cu(II) were assessed by different  techniques 
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such as elemental analysis, spectral methods [Fourier transform infrared spectroscopy (FTIR), 
FT-Raman spectrometry, mass spectrometry], and scanning electron microscopy (SEM) cou-
pled with X-ray spectroscopy [energy-dispersive spectroscopy (EDS)] [1, 10–13].
The elemental analysis indicated that the combination ratio of metal:ligand (Me:L) is 1:2 for 
[Cu(PZA)
2
]Cl
2
 and [Cu(PZA)
2
](C
6
H
5
COO)
2
 complexes. The mass spectra of the complex of 
PZA with Co(II) benzoate revealed the identity and the purity of PZA and of the complex 
fragments confirming its structure (Figure 1) [1, 10].
The FTIR spectra of the complexes highlighted that –C═O groups and nitrogen from the 
pyrazine ring are implied in the coordination process (Table 1) [11]. Comparing the Raman 
spectra of PZA and of [Cu(PZA)
2
]Cl
2
, another analytical evidence for the complex formation 
is obtained. The appearance of new band characteristic for the Me:L bonds can be observed 
analyzing in detail the spectral region of low values of wave number (Figure 2) [1, 11, 12].
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Figure 1. The mass spectra of PZA (A) and [Cu(PZA)
2
](C
6
H
5
COO)
2
 (B) [1, 10]. Reprinted with permission of Revista de 
Chimie and of Editura Universităţii din Oradea.
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PZA [Cu(PZA)
2
](C
6
H
5
COO)
2
[Cu(PZA)
2
]Cl
2
Assignment
3410s 3610w 3430s νas NH2
3140m 3170m 3110m νs NH2
3080 3065m 3070m νCH
1705s 1915w 1700s νC═O(1)
1600m 1590m 1590m δNH
2
(2)
1570 1585m 1585m ν ring
1530 1545s 1510w ν ring
1375s 1380s 1385s νCN(III)
1150w 1180w 1170m δCH
1090m 1085w 1080w ρ NH
2
870w 850w 870m δ ring
665w 680m 670w ρ NH
2
Note: v, very; s, strong; m, medium; w, weak; ν, stretching; δ, in plane bending; ρ, rocking.
Source: Reprinted with permission of Farmacia and of Editura Universităţii din Oradea.
Table 1. Assignment of the characteristic IR bands of the metal complexes of PZA [1, 14].
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Figure 2. Raman spectra of PZA and of [Cu(PZA)
2
]Cl
2
 [1, 12]. Reprinted with permission of Studia Universitatis Babes-
Bolyai and of Editura Universităţii din Oradea.
Metal Complexes of Pharmaceutical Substances
http://dx.doi.org/10.5772/65390
127
The morphology and the crystal structure of the two complexes were revealed by the SEM 
images and EDS spectra (Figures 3 and 4). The first complex, [Cu(PZA)
2
](C
6
H
5
COO)
2
, pre-
sented irregular conglomeration with different shapes and dimensions (Figure 3A); mean-
while, the second one, Cu(PZA)
2
]Cl
2
, presented acicular and elongated particles with an 
average size of about 1.5 microns (Figure 4A) [1, 14].
2.2. Metal complexes of nicotinamide
Nicotinamide (NAM) (3-pyridine carboxylic acid amide) is the amide of nicotinic acid playing 
an important role in the biosynthesis of pyridine nucleotides, and it is a reactive moiety of the 
coenzyme nicotinamide adenine dinucleotide, a soluble electron carrier in biochemical reac-
tions. The NAM complexes with transition metals [Cu(II), Cd(II), Hg(II)] were synthesized 
and characterized by using elemental analysis, UV-Vis, and FTIR spectroscopy [1, 15, 16]. 
The spectral data confirmed tetradentate coordination of NAM with Hg(II), Cd(II), and hexa-
dentate coordination with Cu(II). In the FTIR spectra of these complexes, it can be observed 
that the characteristic bands of NAM are slightly shifted after coordination (Table 2) [16]. The 
slight shifting of the bands from NAM complexes with Hg may be explained by the stereo-
chemistry of HgCl
2
, which is less bulky than Cu(C
6
H
5
COO)
2
 and Cd(SCN)
2
.
2.3. Metal complexes of nicotinic acid
Nicotinic acid (NIC) (pyridine-3-carboxylic acid) known as vitamin B3, niacin, has two impor-tant pharmacological properties: peripheral vasodilator and hypocholesterolemic drug. Its 
 complexes with Co(II) and Cu(II) were synthesized and characterized by elemental analy-
sis and spectral methods [FTIR spectroscopy, Raman spectroscopy, and  surface-enhanced 
Figure 3. SEM image (A) and EDS spectrum (B) of [Cu(PZA)
2
](C
6
H
5
COO)
2
 [1, 14]. Reprinted with permission of Farmacia 
and of Editura Universităţii din Oradea.
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Raman  spectroscopy (SERS)] (Figure 5). The significant differences observed from the spec-
tral data of the metal complexes can be attributed to the coordination process with the 
metal ions: the stretching vibrations ν(C─C) from the pyridine ring (1500–1600 cm−1) and 
ν(ring) of NIC (1037 cm−1) are shifted; meanwhile, the vibration band γ(CH) of the ring at 
811 cm−1 is shifted and also splitted indicating the ring deformation during the coordina-
tion process. There appear new bands corresponding to the Me:L bonds (at about 500 cm−1) 
(Table 3). The spectral results confirmed the monodentate coordination of NIC with Cu(II) 
and Co(II) [17].
2.4. Metal complexes of guanfacine
Guanfacine (GUAF) (N-(diaminomethylidene)-2-(2,6-dichlorophenyl)acetamide), used as 
antihypertensive drug, is able to form colored complexes (combination ratio Me:L 1:2) with 
Mn(II) and Cd(II) having different spectral characteristics. These complexes were analyzed 
by using spectral techniques such as FTIR and Raman spectroscopy. The imine group vibra-
tion from the FTIR data of GUAF (ν C═N at 1700 cm−1) was shifted (Δ = 10–60 cm−1) in the spectra of GUAF complexes with Mn(II) (ν C═N at 1710 cm−1) and Cd(II) (ν C═N at 1760 cm−1) showing the imine group involvement in the complex formation. The formation of new 
bonds Me:L was observed at around 500 cm−1 in the case of the two mentioned complexes. 
Significant differences appeared in the Raman spectra of the complexes in the region 1100–
1250 cm−1 due to the electronic delocalization from NH═C─NH
2
 (Figure 6). After coordi-
nation, in the case of both complexes, two distinct bands were revealed at 1212 cm−1 for 
NH─C─NH
2
 and at 1174 cm−1 for NH═C─NH
2
. The spectral data indicated that GUAF is 
coordinated by nitrogen atoms, and the results confirmed a tetradentate coordination of 
Cd(II) complexes [18].
Figure 4. SEM image (A) and EDS spectrum (B) of [Cu(PZA)
2
]Cl
2
 [1, 14]. Reprinted with permission of Farmacia and of 
Editura Universităţii din Oradea.
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2.5. Metal complexes of theophylline
Theophylline (TEO) (3,7-dihydro-1,3-dimethyl,1H-purine-2,6-dione) also known as 1,3-dimethyl-
xanthine belongs to the class of peripheral and cerebral vasodilator drugs. Metal complexes of 
TEO were synthesized having the general formula: [Me
n
(TEO)x]Am ⋅ yH2O, where Me = Cu(II), Co(II), Cd(II), Zn(II), and Ni(II) and A = CH3COO−, C6H5COO−; n = 1, x = 1 or 2, m = 2, and y = 2 or 4. The combination ratio was determined by using elemental analysis and conductometric 
titration; meanwhile, the number of water molecules was determined by using thermal analysis 
[2, 19–22].
NAM [Hg(NAM)
2
]Cl
2
[Cu(NAM)
2
] 
(C
6
H
5
COO)
2
2H
2
O
[Cd(NAM)
2
](SCN)
2
Assignment
3531w (OH)
3364vs 3363s 3369s 3479s νas(NH2)
3167s 3171s 3207vs 3176m νs(NH2)
3065sh 3071sh 3071sh 3072w ν(CH)
1654s 1654vs 1668vs 1667vs ν(CO)
1622ws 1623ws 1632ws 1618m δ(NH
2
)
1577ws 1577vs 1596s 1577s ν(CN) + ν(CC)
1449m 1449m 1490s 1485m β(CH)
1395ws 1400m 1377vs 1400s ν(CN) amide
1297m 1296m 1301w 1331m ν(CC)
1178m 1179m 1193w 1204s ν(ring) NAM
1141m 1142s 1153sh 1153m ν (CN)
1120m 1119s 1116m 1112m ρ(NH
2
)
1022m 1024w 1025m 1040m υ(CNS)
– 919m 928w 937w γ(CH) ring
– 844s 853m 840m νas(C─CH3)
771m 786s 775w 770s γ(CH) ring
698m 700ws 719w 719w ω(NH
2
)
684m 686ws 687s 687ws δ(ring)NAM
633s 641s 655w 657ws γ(NH)
Note: v, very; s, strong; m, medium; w, weak; sh, shoulder; sp, splitting; ν, stretching; β, in-plane bending; γ, out-of-plane 
bending; δ, in-plane bending; ω, out-of-plane wag.
Source: Reprinted with permission of Revista de Chimie.
Table 2. Assignment of the characteristic IR bands of the metal complexes of NAM [16].
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Figure 5. Raman (A) and SERS (B) spectra of NIC (a) and its complex with Cu(II) (b) and Co(II) (c) [17]. Reprinted with 
permission of Revista de Chimie.
Assignment 
(cm−1)
NIC Raman 
(cm−1)
NIC SERS 
(cm−1)
Cu(NIC)
2
 
(CH
3
COO)
2
 
Raman (cm−1)
Cu(NIC)
2
 
(CH
3
COO)
2
 
SERS (cm−1)
Co(NIC)
2
 
(CH
3
COO)
2
 
Raman (cm−1)
Co(NIC)
2
 
(CH
3
COO)
2
 
SERS (cm−1)
ν(OH) acid – – – – – –
ν(CH) – – – – – –
νC═O 1690m – – – – –
ν(ring) NIC 1594m 1594m 1594m – 1584m –
ν(CN) – – – – – –
– 1377m 1371m 1377wv 1389s 1377wv
ν(CC) 1298m – – – – –
δ(CN) 1180m – – – 1198m –
ν(ring)NIC 1037vs 1029s 1033vs 1060wv 1029vs 1061wv
δ(OH)acid – – – 931m – 931m
γ(CH) ring 811m 838wv 846m 760wv 829m 755wv
δ(CH) ring 638m 653wv 642m – 638m 648wv
νMe-O – – 555wv 509wv – 504wv
Note: v, very; s, strong; m, medium; w, weak; ν, stretching; γ, out-of-plane bending; δ, in-plane bending.
Source: Reprinted with permission of Revista de Chimie.
Table 3. Assignment of the characteristic Raman and SERS bands of the metal complexes of NIC [17].
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The combination ratio Me:TEO is 1:2 for the complexes having the acetate anion. The complex 
[Cu(TEO)
2
](CH3COO)2 has a high thermal instability even at 40°C, its thermal decomposi-tion being already started. On the thermal curves, eight stages of decomposition, all scarcely 
separable, can be observed. The first five were weakly endothermic, and three were strongly 
exothermic. The X-ray diffractogram revealed that this complex crystallizes in the monoclinic 
system. The microscopic analysis showed a mixture of particles with different shapes: acicu-
lar, flake, irregular, and lamellar (Figure 7) [2, 19–22].
In the case of [Cd(TEO)
2
](CH3COO)2, the last stage of thermal decomposition was not achieved in the investigated temperature range; therefore, heating was required up to a higher tem-
perature (850°C) when constant weight was reached corresponding to the cadmium oxide. 
The complex crystallizes in the monoclinic system, and it presents microcrystals with paral-
lelepiped shape (Figure 8) [2, 19, 21, 22].
The thermal decomposition of [Co(TEO)
2
](CH3COO)2 takes place in four stages: one endo-thermic and three exothermic. It presents monoclinic crystal system, and the microcrystals 
have a tabular form (Figure 9). The complex [Zn(TEO)
2
](CH3COO)2 presented similar proper-ties as [Cd(TEO)
2
](CH3COO)2 complex [2, 19, 21, 22].
The endothermic peak at 272°C, which is characteristic for TEO decomposition, is not found 
in the differential scanning calorimetry (DSC) curves of the complexes, being a credible 
argument for the complex synthesis and not as a simple mechanical mixture (Figure 10) 
[2, 19].
Figure 6. Raman spectra of GUAF and of its metal complexes [19].
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The FTIR data also indicated the complex formation: the disappearance of the symmetric 
vibration band of ─C═O from TEO at 1717 cm−1 in the complexes spectra indicating that this 
bond is involved in the formation of Me:TEO coordinative bond; the deformation vibration 
of Me:N bond found at 570–685 cm−1, the appearance of symmetric and asymmetric stretch-
ing vibrations of the ─COOH group (1260–1250 and 1535–1530 cm−1), and the possibility of 
coordinating also the water of crystallization (appearance of large bands at 3050–3500 cm−1) 
(Figure 11) [2, 19, 21, 22].
The combination ratio Me:TEO is 1:1 for the complexes having the benzoate anion: [Co(TEO)]
(C
6
H
5
COO)
2
·2H
2
O, [Ni(TEO)](C
6
H
5
COO)
2
·2H
2
O, and [Cu(TEO)](C
6
H
5
COO)
2
·2H
2
O. Their 
thermal decomposition takes place in four stages, the first one being the stage of loss of 
water of crystallization (Figure 12A). The FTIR data are similar with those of the complexes 
 mentioned above (having the acetate group as anion); in addition, the specific vibration band 
Figure 7. Thermogramms TG, DTG, and DTA (A); X-ray diffractogram; (B) and SEM images (C) of [Cu(TEO)
2
](CH3COO)2 [2, 19, 21, 22]. Reprinted with permission of Revista de Chimie, Farmacia and of Editura Politehnica Timişoara.
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of the aromatic ring (1438, 1442, 1440 cm−1) appears. The microscopic image of [Co(TEO)]
(C
6
H
5
COO)
2
 showed the acicular shape of the particles (Figure 12B) [2, 20].
2.6. Metal complexes of captopril
The chemical structure of captopril (CPL), a dipeptide derivative of L-alanine-L-proline with 
antihypertensive effect, contains bonds such as ─C═O and ─N(─CH
2
)
2
 with donor atoms 
capable of forming Me:L bonds. The interaction between the metal ions such as Mn(II), Co(II), 
Zn(II), Ni(II), and Cd(II) with N and O atoms from the peptide (which act as donors) leads 
to the formation of stable chelate cycles. These complexes were characterized by elemental 
analysis obtaining the results presented in Table 4 [23, 24].
CPL forms complexes with transition metals mentioned above in the presence of tetraiodo-
mercurate anion, [HgI
4
]2−. The formation and the structure of these complexes are observed in 
the data of the elemental analysis and in the UV and IR spectra of the complexes with changes 
of the wavelength values and of absorbance due to the presence of Me:CPL bonds. In the IR 
spectra of the complexes, a diminution of the band at 1748 cm−1 of ─C═O from the carboxyl 
group, in comparison with the IR spectrum of CPL, was observed. A wider band appeared 
Figure 8. Thermogramms TG, DTG, and DTA (A); X-ray diffractogram; (B) and SEM images (C) of [Cd(TEO)
2
](CH3COO)2 [2, 19, 21, 22]. Reprinted with permission of Revista de Chimie, Farmacia and of Editura Politehnica Timişoara.
Spectroscopic Analyses - Developments and Applications134
at 1600 cm−1 due to the overlapping of the bands corresponding to ─C═O from the amide 
group. In addition, a new band is observed at 1450 cm−1 due to ─C═O from the carboxyl 
group (─COO−). In the IR spectra of the Zn:CPL complex, the band corresponding to ─C═O 
from carboxyl group decreased. It is possible that the reaction with some metals was not com-
pletely performed or some degradation products of CPL may be involved in the complexation 
reaction. In the case of the complex Cu
2
IICPL
2
(H
2
O)
2
, the IR spectra have indicated the partici-
pation of ─COOH, ─C═O, and ─SH groups in coordination along with H
2
O included in the 
inner coordination sphere [23, 24].
The UV spectra of the complexes were compared to the UV spectrum of CPL in dimethylfor-
mamide establishing the parameters presented in Table 5 (A%1 cm = 190 for 2.5 μg% CPL) [23, 24].
2.7. Metal complexes of tolbutamide
Tolbutamide (TBA) (N-p-tolylsulfonyl-N′-n-butylcarbamide) is the first generation of sul-
fonylurea oral hypoglycemic drug. Three complexes of TBA with Cu(II) were synthesized, 
Figure 9. Thermogramms TG, DTG, and DTA (A); X-ray diffractogram; (B) and SEM images (C) of [Co(TEO)
2
](CH3COO)2 [2, 19, 21, 22]. Reprinted with permission of Revista de Chimie, Farmacia and of Editura Politehnica Timişoara.
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Figure 10. DSC thermogramms of metal complexes of TEO [2, 19]. Reprinted with permission of Revista de Chimie and 
of Editura Politehnica Timişoara.
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Figure 11. FTIR spectra of TEO and of its metal complexes (acetate anion).
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[Cu(TBA)
2
](SCN)2, [Cu(TBA)2]Cl2·2H2O, and [Cu(TBA)2][Hg(SCN)4].H2O and then were characterized by elemental analysis, FTIR spectroscopy, electron paramagnetic resonance 
(EPR) spectroscopy, and thermal methods establishing the combination ratio Cu:TBA 1:2, 
the presence of water of crystallization, and the coordination system. The FTIR spectral 
studies indicated that the three mentioned complexes were coordinated through the car-
bonyl group. The EPR spectra showed that the Cu2+ ions were disposed in an octahedral 
vicinity of axial symmetry with a different hyperfine structure of the three complexes 
[25–27].
Figure 12. Thermogramms TG, DTG, and DTA (A) and SEM images (B) of [Co(TEO)](C
6
H
5
COO)
2
 [2, 20]. Reprinted with 
permission of Revista de Chimie and of Editura Politehnica Timişoara.
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The molecular  
formula and weight
Color Melting point 
(°C)
C%
Found/
calculated
H%
Found/
calculated
N%
Found/
calculated
S%
Found/
calculated
[Cd(CPL)
2
][HgI
4
] 
M = 1255.18
White 210 17.09/17.21 2.56/2.39 1.881/2.23 5.579/5.099
[Zn(CPL)
2
][HgI
4
] 
M = 1244.18
White 165 16.94/17.8 3.019/2.48 1.866/2.31 5.547/5.29
[Ni(CPL)
2
][HgI
4
] 
M = 1199.48
Greenish 
yellow
170 18.07/18.01 3.022/2.5 1.955/2.33 6.083/5.33
[Co(CPL)
2
][HgI
4
] 
M = 1199.68
Light pink 180 17.84/18.01 2.866/2.51 1.938/2.31 6.148/5.43
[Mn(CPL)
2
][HgI
4
] 
M = 1195.68
White crystals 182 18.04/18.06 2.648/2.50 1.946/2.34 5.85/5.35
Source: Reprinted with permission of Farmacia and of Editura Universităţii din Oradea.
Table 4. Physicochemical characterization of the metal complexes of CPL [23, 24].
Complex λ (nm) A%
1 cm
Concentration (μg %)
CPL–Cd 300 270 5
CPL–Zn 300 400 5
CPL–Ni 300 475 4
CPL–Co 300 250 8
CPL–Mn 321 520 4.5
Source: Reprinted with permission of Editura Universităţii din Oradea.
Table 5. The parameters of the metal complexes of CPL from UV spectra [23].
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Figure 13. Raman spectra of CLN and of its metal complexes.
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2.8. Metal complexes of clonidine
Clonidine (CLN) (2[(2,6-dichlorophenyl)imino]-imidazolidine) is a centrally acting α
2
 adre-
nergic agonist used as antihypertensive drug. Metal complexes of CLN such as [Me(CLN)
2
]
[HgI
4
] where Me = Cd(II), Mn(II), Ni(II), and Cu(II) were synthesized and studied by ele-
mental analysis, FTIR spectroscopy, Raman spectroscopy (Figure 13), and EPR spectroscopy 
confirming the structure and the changes in the complex conformation [28].
3. Biomedical significance of metal complexes with pharmaceuticals
The study of the complexes structure and of their biological importance represented the major 
research interest toward the use of organic drugs as ligands in coordination chemistry for 
their application in the biomedical field.
The molecules of the pharmaceutical substances have one or more unshared electron pairs 
that can function as ligands. In fact, many of the basic components of living organisms (amino 
acids, peptides, proteins, hormones, lipids, carbohydrates, etc.) may function as ligands because 
they contain donor atoms in their molecules such as nitrogen, oxygen, sulfur, and phospho-
rus. It is well known that many molecules of drug substances act as ligands both in vitro and 
in vivo conditions. It is noteworthy to mention that in vivo these ligands will compete for a 
particular metal ion with a variety of other ligands determining that the extrapolation of this 
in vitro behavior should be done with moderation. It should always be taken into consider-
ation that the therapeutic effect will be mainly influenced by the conformation of the drug 
ligands molecules and by their ability to combine with receptors.
Thus, the use of these metal complexes in the biomedical field can be realized by various 
purposes such as the introduction in the body of deficient metal ions, the use of the ligands 
as antidotes in various intoxications with metals, and the acquirement of pharmacotherapy 
effects by blocking metal ions essential for some enzymatic systems. Metal ions are of great 
importance not only in the vital functions of living organisms, but also they can be intensively 
used in analysis and control methods for pharmaceutical substances by forming complexes 
that can be detected by using different physicochemical methods such as spectroscopy, chro-
matography, microscopy, etc.
4. Conclusions
Transition metal complexes find their application in catalysis, material synthesis, photo-
chemistry, therapy, and diagnostics. Various chemical, optical, and magnetic properties of 
the metal complexes of some pharmaceutical substances (pyrazinamide, nicotinamide, nico-
tinic acid, tolbutamide, theophylline, captopril, clonidine, and guanfacine) have been studied 
by using a wide range of techniques. The spectral methods such as Fourier transform infra-
red spectroscopy, Raman spectroscopy, surface-enhanced Raman spectroscopy, X-ray spec-
troscopy, mass spectrometry, ultraviolet-visible spectrophotometry, electron paramagnetic 
resonance spectroscopy, and X-ray diffraction provided information about the complexes 
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and ligand structure. Other techniques such as elemental analysis, electrochemical, and ther-
mal methods were also employed for the assessment of the complexation ratio. The scanning 
electron microscopy images revealed the morphology of the metal complexes underlying 
their crystalline or amorphous character. Many studies were conducted concerning the syn-
thesis and the investigation of metal complexes in which the pharmaceutical substances play 
the role of ligand highlighting their increasing clinical and commercial importance.
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